Brief: Resmed Q1 Adjusted EPS USD 2.2 Vs. IBES Estimate USD 2.04
24/10/2024 21:05
Oct 24 (Reuters) - Resmed Q1 revenue USD 1,200 million vs. IBES estimate USD 1,180 million. * Q1 gross margin 58.6% * Q1 EPS USD 2.11 * Q1 adjusted gross margin 59.2%
Recent news on ResMed
See all newsCiti lifts ResMed's ASX-listed stock's target price after FX, valuation updates
S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT
S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT
Brief: Resmed - Enters Accelerated Share Repurchase Agreement To Repurchase $450 Million Of Common Stock - SEC Filing
S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT